Brief: Sinomab Bioscience Says For Suciraslimab, Preliminary Result For Phase Iii Study At Week 24 Is Expected In Q3
05/09/2022 15:46
Sept 5 (Reuters) - SinoMab BioScience 3681.HK :
* FOR CO'S PRODUCT SUCIRASLIMAB, PRELIMINARY RESULT FOR
PRIMARY
ENDPOINT OF PHASE III STUDY AT WEEK 24 IS EXPECTED IN Q3 OF 2022
* CO PLANS TO SUBMIT NEW DRUG APPLICATION FOR SUCIRASLIMAB
TO NMPA
IN FIRST HALF OF 2023
* EXPECTS TO COMMERCIALISE SUCIRASLIMAB IN SECOND HALF OF
2023 AT
EARLIEST
Source text for Eikon: ID:nHKSbfm81g
Further company coverage: 3681.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinomab Bioscience
See all newsBrief: Sinomab Bioscience Posts HY Loss Of RMB127.4 Million
Brief: Sinomab Bioscience Says Fang Liang Resigns As Executive Director
Brief: Sinomab Bioscience Announces Major Deal For Disposal Of Suzhou Property And Facility For RMB280 MLN
Brief: SinoMab Bioscience Appoints Fang Liang As Executive Director
Brief: Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience